The SELECT Trial 3D Cohort Map: Understanding Semaglutide's Cardiovascular Benefits

What the SELECT Trial Is

The SELECT (Semaglutide Efficacy and Cardiovascular Outcomes Long-term) trial is a large-scale clinical study designed to evaluate the long-term cardiovascular safety of semaglutide, an injectable glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) agonist. The trial primarily focuses on assessing whether semaglutide can reduce major adverse cardiovascular events (MACE), such as myocardial infarction and stroke.

The SELECT trial involved over 9000 patients with type 2 diabetes, randomly assigned to receive either semaglutide or placebo in addition to standard care. The study aimed to determine the efficacy of semaglutide in reducing cardiovascular risks while also examining its impact on weight loss and inflammation.

How the 3D Cohort Map Works

The 3D cohort map provides a visual representation of the SELECT trial data, with two patient-cohort lattices floating in separate depth planes. One lattice represents patients receiving semaglutide (near), while the other shows those on placebo (far). Each lattice is composed of patient spheres that turn red when they experience an event such as weight loss or a cardiovascular adverse event.

A Kaplan-Meier survival ribbon rises above these lattices, showing the probability of remaining event-free over time. This ribbon is updated in real-time as you adjust the follow-up months slider, providing dynamic insights into the trial's outcomes.

Key Findings and Mechanisms

The SELECT trial demonstrated that semaglutide significantly reduced MACE compared to placebo. This reduction was attributed to its ability to lower body weight and hs-CRP (high-sensitivity C-reactive protein), a marker of inflammation. The 3D cohort map allows you to explore these mechanisms by observing the changes in patient spheres over time, with red spheres indicating events such as weight loss or MACE.

The 3D representation also includes grouped bars for weight and hs-CRP change, providing a clear visual summary of how semaglutide affects these parameters. The genuine 3D survival curve further enhances understanding by showing the progression of event-free survival in both cohorts.

Why It Matters

Understanding the SELECT trial results is crucial for healthcare providers, researchers, and patients because it provides robust evidence supporting the use of semaglutide as a safe and effective treatment for type 2 diabetes. The cardiovascular benefits observed in the trial have significant implications for reducing the risk of major adverse events in this patient population.

Moreover, the SELECT trial has set new standards for evaluating the long-term safety and efficacy of GLP-1/GIP agonists, influencing future clinical trials and regulatory decisions.

Frequently asked questions

Try it live

Everything above runs in your browser — open SELECT Trial 3D Cohort Map — Semaglutide CV Outcome Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.